Amneal Aims To Expand Internationally
As Firm Lines Up Pipeline And Develops Biosimilars Business
Amneal has laid out ambitious plans for 2020 to deliver value and volume growth, including by expanding internationally, augmenting organic growth through M&A and capitalizing on its pipeline of ANDAs and development projects. The firm will seek to build on its launch of 38 products in 2019 as well as benefiting from recent key appointments to its board.
You may also be interested in...
Two familiar industry figures have bolstered Amneal’s board, while Latvia’s Olanfarm has turned to a Sanofi executive for external expertise. Meanwhile, both Taro and Pfenex are recruiting CFOs.
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”
Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.